Concepedia

Author

Elena Polverejan

Johnson & Johnson (United States)ORCID

Also Known As

E Polverejan, E. Polverejan, Elena Polverejan, Panna Sanga

31

Publications

934

Citations

12

H-Index

45

Concepts

All Affiliations

Johnson & Johnson (United States)Janssen (United States)Tufts UniversityUniversity of Illinois Urbana-ChampaignMichigan State University
EP

About

Elena Polverejan is an author at Johnson & Johnson (United States) specializing in medicine, neuroscience, and health sciences.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

360

2

Health Sciences

2

2

297

3

Social Sciences

2

2

229

4

Engineering

1

1

19

5

Public Health

1

1

199

Elena Polverejan

×

13

Publications

909

Citations

12

H-Index

YearCitations

Premature Ejaculation: Results from a Five-Country European Observational Study

François Giuliano, Donald L. Patrick, Hartmut Porst,

European Urology

2007

199

Impairments of memory and learning in older adults exposed to polychlorinated biphenyls via consumption of Great Lakes fish.

Susan L. Schantz, Donna M. Gasior, Elena Polverejan,

Environmental Health Perspectives

2001

192

Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for Migraine Prevention in Pediatric Subjects 12 to 17 Years of Age

Donald W. Lewis, Paul Winner, Joel R. Saper,

PEDIATRICS

2009

148

Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain

Panna Sanga, Nathaniel P. Katz, Elena Polverejan,

Pain

2013

105

Estimating mean hospital cost as a function of length of stay and patient characteristics

Elena Polverejan, Joseph C. Gardiner, Cathy J. Bradley,

Health Economics

2002

91

Cognitive Effects of Topiramate in Migraine Patients Aged 12 Through 17 Years

Gahan Pandina, Seth Ness, Elena Polverejan,

Pediatric Neurology

2010

37

Long‐Term Safety and Efficacy of Fulranumab in Patients With Moderate‐to‐Severe Osteoarthritis Pain: A Phase II Randomized, Double‐Blind, Placebo‐Controlled Extension Study

Panna Sanga, Nathaniel P. Katz, Elena Polverejan,

Arthritis & Rheumatology

2016

37

Efficacy, Safety, and Tolerability of Fulranumab as an Adjunctive Therapy in Patients With Inadequately Controlled, Moderate-to-Severe Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Dose-loading Phase II Study

Panna Sanga, Elena Polverejan, Steven Wang,

Clinical Therapeutics

2016

29

Aligning Treatment Policy Estimands and Estimators—A Simulation Study in Alzheimer’s Disease

Elena Polverejan, Vladimir Dragalin

Statistics in Biopharmaceutical Research

2019

19

Defining Clinical Trial Estimands: A Practical Guide for Study Teams with Examples Based on a Psychiatric Disorder

Elena Polverejan, Michael O’Kelly, Nanco Hefting,

Therapeutic Innovation & Regulatory Science

2023

15

Page 1